Literature DB >> 12476102

Diabetic papillopathy in type II diabetic patients.

Zerrin Bayraktar1, Nilay Alacali, Sükrü Bayraktar.   

Abstract

PURPOSE: To evaluate the patient characteristics and fundus findings of patients with type II diabetes presenting with diabetic papillopathy.
METHODS: The authors retrospectively reviewed the medical records of 3,235 patients with diabetes followed in their institution since 1986 and identified the patients with unilateral or bilateral transient disk swelling and without significant deterioration of best-corrected visual acuity. The authors investigated patient demographics, symptoms, fundus findings, ancillary test results, and clinical course of those patients.
RESULTS: Twenty-four eyes of 16 patients with type II diabetes mellitus met the criteria. Patients had a mean age of 57.1 (+/-8.8) years and had diabetes mellitus of long duration (mean 10.0 +/- 8.6 years). Approximately half of the patients had poor metabolic control. Disk swelling was bilateral in 8 (50%) patients and resolved in an average of 7.8 +/- 3.7 months. A total of 13 (54%) eyes had nonproliferative and 2 (8%) eyes had proliferative diabetic retinopathy at presentation. In 4 (17%) eyes retinopathy progression into the proliferative stage occurred and panretinal photocoagulation was performed.
CONCLUSIONS: Diabetic papillopathy may be found in older patients with type II diabetes. Nonproliferative or proliferative diabetic retinopathy as well as macular edema may also be associated with this disorder.

Entities:  

Mesh:

Year:  2002        PMID: 12476102     DOI: 10.1097/00006982-200212000-00011

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  12 in total

Review 1.  Ocular complications of diabetes mellitus.

Authors:  Nihat Sayin; Necip Kara; Gökhan Pekel
Journal:  World J Diabetes       Date:  2015-02-15

2.  Regional brain changes in patients with diabetic optic neuropathy: a resting-state functional magnetic resonance imaging study.

Authors:  Si-Yi Chen; Guo-Qian Cai; Rong-Bin Liang; Qi-Cheng Yang; You-Lan Min; Qian-Min Ge; Biao Li; Wen-Qing Shi; Qiu-Yu Li; Xian-Jun Zeng; Yi Shao
Journal:  Quant Imaging Med Surg       Date:  2021-05

3.  Response of diabetic papillopathy to intravitreal bevacizumab.

Authors:  Hassan Al-Dhibi; Arif O Khan
Journal:  Middle East Afr J Ophthalmol       Date:  2011-07

4.  Diabetic papillopathy with macular edema treated with intravitreal bevacizumab.

Authors:  Ahmed S Al-Hinai; Mohammed S Al-Abri; Rayah H Al-Hajri
Journal:  Oman J Ophthalmol       Date:  2011-09

5.  Bilateral disc drusen in a diabetic patient simulating diabetic papillopathy as a cause of disc edema.

Authors:  Rohan Chawla; Soman Nair; Pradeep Venkatesh; Satpal Garg; Kanhaiya Mittal
Journal:  Indian J Ophthalmol       Date:  2017-10       Impact factor: 1.848

6.  Diabetic papillopathy treated with intravitreal ranibizumab.

Authors:  Mine Yildirim; Deniz Kilic; Mehmet Emin Dursun; Birgul Dursun
Journal:  Int Med Case Rep J       Date:  2017-03-22

7.  Swept-source optical coherence tomography angiography findings of diabetic papillopathy after intravitreal bevacizumab.

Authors:  In Hwan Cho; Dae Joong Ma
Journal:  Am J Ophthalmol Case Rep       Date:  2020-05-16

8.  The Prevalence and Causes of Visual Impairment in Type 2 Diabetes Mellitus in Northeast China.

Authors:  Liang Wen; Yu Wang; Zhong Lin; Feng Hua Wang; Xiao Xia Ding; Dong Li; Kemi Feng; Yuan Bo Liang; Dong Xiao Zhang; Yu Dou; Gang Zhai
Journal:  J Ophthalmol       Date:  2020-11-29       Impact factor: 1.909

9.  Non-invasive Diagnosis and Prognosis Values of 3D Pseudocontinuous Arterial Spin Labeling and Optical Coherence Tomography Angiography in Proliferative Diabetic Retinopathy.

Authors:  Yanli Hou; Shuai Song; Jiao Sun; Huihui Wang; Yanling Wang; Zhenchang Wang; Jing Li; Hongyang Li
Journal:  Front Med (Lausanne)       Date:  2021-06-04

10.  Diabetic papillopathy with macular edema treated with intravitreal ranibizumab.

Authors:  Moosang Kim; Jang-Hun Lee; Seung-Jun Lee
Journal:  Clin Ophthalmol       Date:  2013-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.